Targeting pathogenic auto-reactive VH4-34 B cells with a rationally developed and highly specific anti-VH4-34 antibody offers a new therapeutic approach for VH4-34 autoimmune disorders
The impact of high-risk antiphospholipid antibodies profile on major organ damage progression in systemic lupus erythematosus: CSTAR multiple prospective cohort study
Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibodies associated adverse pregnancy outcomes: a based on a 13-year longitudinal cohort study
Deucravacitinib reduces interferons, B cell pathways, and serological biomarkers of systemic lupus disease activity: Pharmacodynamic analysis from the phase 2 PAISLEY study
Activated leukocyte cell adhesion molecule, hemopexin, and peroxiredoxin 6 as a potential urine biomarker for Korean patients with Systemic Lupus Erythematosus
The neutrophil-to-C3 ratio (NC3R) was an inflammatory marker in the assessment of lupus nephritis and ocular vessel density in systemic lupus erythematosus patients
Comparison between add-on pulse methylprednisolone versus medium to high dose glucocorticoids alone in Thai patients with proliferative lupus nephritis receiving monthly pulse intravenous cyclophosphamide
Predictors of de novo renal flares in systemic lupus erythematosus – time to revisit belimumab dose for extra-renal disease? Results from five phase III clinical trials of belimumab
Comparison of the systemic lupus international collaborating clinics frailty index (SLICC-FI) and the FRAIL scale for identifying frailty among individuals with systemic lupus erythematosus
Association of latent tuberculosis infection with clinical and serological parameters in systemic lupus erythematosus- a prospective observational study
Withdrawal of maintenance glucocorticoid versus other immunosuppressants among patients with Systemic Lupus Erythematosus in long term clinical remission: Interim analysis of a non-inferiority randomised controlled trial
Overlap syndrome of systemic sclerosis with antineutrophil cytoplasmic antibody-associated vasculitis according to the 2022 ACR/EULAR classification criteria
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in a phase 2 trial in systemic lupus erythematosus (SLE): achievement of sustained SRI(4), BICLA, and dual responses over 48 weeks
Zetomipzomib (KZR-616) demonstrates anti-inflammatory and immunomodulatory potential in patients with active lupus with or without lupus nephritis: Results from the open-label Phase 1b/2 MISSION study
Association of healthy lifestyles with all-cause and cause-specific mortality among individuals with osteoarthritis: A prospective cohort study of the UK biobank
Recovery and long-term renal outcome of patients with ANCA-associated vasculitis who are on dialysis at presentation
KO-010
Application of the 2022 ACR/EULAR classification criteria for ANCA-associated vasculitis to patients with polymyositis and dermatomyositis presenting clinical manifestations suggestive of small- and medium-vessels vasculitis
Non-alcoholic fatty liver disease fibrosis score is a useful index for predicting all-cause mortality during the follow-up in patients with antineutrophil cytoplasmic antibody-associated vasculitis
Analysis of appropriate duration of colchicine prophylaxis to maximize the persistence of xanthine oxidase inhibitors as the first-line urate lowering therapy in patients with gout using HIRA database
Analysis of appropriate duration of colchicine prophylaxis to maximize the persistence of xanthine oxidase inhibitors as the first-line urate lowering therapy in patients with gout using HIRA database
Breakthrough SARS-CoV-2 infection in fully vaccinated patients with systemic lupus erythematosus: Results from the COVID-19 Vaccination in Autoimmune Disease (COVAD) study
Interim safety and efficacy of subcutaneous (s.c.) dose ianalumab (VAY736; anti-BAFF-R mAb) administered monthly over 28 weeks in patients with systemic lupus erythematosus (SLE)
Risk of cancer, cardiovascular disease, thromboembolism, and mortality in rheumatoid arthritis with janus kinase inhibitors: Data from Korean health insurance data
KO-025
Risk of cancer, cardiovascular disease, thromboembolism, and mortality in rheumatoid arthritis with janus kinase inhibitors: Data from Korean health insurance data
Risk of major adverse cardiovascular events following targeted therapy according to cardiovascular disease history in patients with rheumatoid arthritis
A spatially-resolved single cell resolution atlas of pediatric lupus nephritis uncovers complex interactions between stromal and infiltrating immune cells.
Urinary neutrophil gelatinase-associated lipocalin (NGAL) as a mediator of the association between particulate matter exposure and disease activity in systemic lupus erythematosus
LSO-043
Urinary neutrophil gelatinase-associated lipocalin (NGAL) as a mediator of the association between particulate matter exposure and disease activity in systemic lupus erythematosus
Genetic fine mapping of independent variants in MHC region associated with predisposition and clinical feature of systemic lupus erythematosus in Han Chinese population
Seung Min Jung (The Catholic Univ. of Korea, Korea)
LSO-058
Changes in clinical features and mortality of early (1998-2007) and late cohort (2008-2017) of systemic lupus erythematosus: A prospective inception cohort study
Impact of time to remission, flares and exposure to immunosuppressives on the development of advanced chronic kidney disease (stage iv or worse) in lupus nephritis
Belimumab in combination with antimalarial agents prevent renal flares in patients with systemic lupus erythematosus and moderate-to-high extra-renal activity: Results from four randomised clinical trials
Association between organ-specific safety of estrogens in lupus erythematosus national assessment-systemic lupus erythematosus (SLE) disease activity index (SELENA-SLEDAI) response to belimumab and SF-36v2 and FACIT-Fatigue scores in patients with SLE
Risk of acute myocardial infarction and stroke associated with anti-rheumatic drugs in patients with rheumatoid arthritis: A nationwide population-based study
Increasing pre-eclampsia knowledge and higher prevalence of aspirin use in SLE with a specific educational tool: Interim analyses of a randomized controlled trial
Longitudinal single-cell transcriptomic analysis of peripheral blood in lupus nephritis reveals different immune cell gene signatures depending on treatment response
Functional characterization of 2p22.3 locus identifies PARP-1 as an allele-specific interactor at rs13385731 which mechanistically regulates rasgrp3 expression in contributing SLE susceptibility
AMP-activated protein kinase modulates the migration of fibroblast-like synoviocytes via SLC7A11-NOX4-ROS signaling in patients with rheumatoid arthritis
A comparative study of pattern of paediatric uveitis in different subtypes of juvenile idiopathic arthritis: Experience from a tertiary care centre in North-West India
The effects and molecular mechanisms of TRAF5 on pulmonary artery endothelial cells in patients with systemic lupus erythematosus associated pulmonary arterial hypertension
Dynamic immune features revealed by single-cell RNA and single-cell TCR/BCR sequencing in patients with rheumatoid arthritis receiving SARS-CoV-2 booster vaccination
Kynurenine pathway can be a potential biomarker of fatigue in primary Sjögren’s syndrome
KO-061
High dimensional cartography of lymphocytes using single-cell mass cytometry differentiates systemic lupus erythematosus and primary Sjögren's syndrome
CHA2DS2-VASc score for prediction of ischemic stroke in patients with systemic lupus erythematosus without atrial fibrillation-RISK of risk scores in the era of artificial intelligence
Correlation of traditional and SLE related risk factors with carotid intima media thickness as early MACEs predictor in SLE patients: A systematic review and meta-analysis
All-cause mortality and the incidence of cancer in patients with moderate-to-severe SLE: Results from the British Isles Lupus Assessment Group Biologics Registry (BILAG-BR)
Identification of an interferon 5-gene signature score as a pharmacodynamic and potential predictive biomarker for deucravacitinib treatment in a phase 2 trial in patients with systemic lupus erythematosus
Genomic prediction model using machine learning techniques that can distinguish autoimmune diseases (RA or SLE) from healthy controls
LSO-082
Withdrawn
May 20(Sat)
14:30-15:30
[Short Oral Presentation]
SLE Pregnancy and Reproductive Health
LUPUS
Conference Room 205A
English
Chair
Sung Hae Chang (Soonchunhyang Univ., Korea)
LSO-083
“Systemic lupus erythematosus Women with lupus nephritis In pregnancy Therapeutic CHallenge (SWITCH)”: The systemic lupus international collaborating clinics experience
Pregnancy outcomes in patients with systemic lupus erythematosus (SLE) , anti-phospholipid antibody syndrome (APL) , scleroderma (SSc) and rheumatoid arthritis (RA) at the Kenyatta national hospital, Nairobi, Kenya
A placebo-controlled phase 1 study in healthy adult volunteers of the safety, tolerability, pharmacokinetics, and pharmacodynamics of povetacicept, a potent dual BAFF/APRIL antagonist, for the treatment of systemic lupus erythematosus
Comparison of COVID-19 vaccination with Influenza vaccination in Korean patients with systemic lupus erythematosus: Perception, adverse events, and flares from the CIVIL study
LUPUS & KCR 2023 Program Book
